Today: 21 May 2026
Vertiv stock jumps on Barclays upgrade — what VRT bulls watch before Monday’s open
5 January 2026
2 mins read

Vertiv stock jumps on Barclays upgrade — what VRT bulls watch before Monday’s open

NEW YORK, Jan 4, 2026, 19:28 ET — Market closed

  • Vertiv shares ended Friday up about 8% after a Barclays upgrade and higher price target.
  • The call refocused attention on 2026 earnings estimates and demand tied to AI data centers.
  • Next catalysts include Monday’s follow-through trade, the U.S. jobs report on Jan. 9 and Vertiv’s next earnings date estimate in mid-February.

Vertiv Holdings Co’s Class A shares (VRT) closed sharply higher on Friday after Barclays upgraded the data-center equipment maker, setting up a test of whether the move holds when U.S. markets reopen on Monday. The stock finished at $175.61, up 8.39% from the prior close, after trading as high as $177.25.

The upgrade matters now because Vertiv has become a high-beta proxy for data center capital spending — money companies put into building and outfitting facilities — and those trades can swing hard on changes in earnings expectations. With rates and growth fears still in the background, investors have been quick to reprice anything tied to the AI buildout.

Vertiv sells power and thermal management gear used in data centers and communications networks. Its “liquid cooling” products — systems that circulate fluid to pull heat away from dense computing racks — have been a focal point as AI workloads push power use higher. Investors

Barclays analyst Julian Mitchell upgraded the stock to Overweight from Equal Weight and raised his price target to $200 from $181, Barron’s reported. “We think the recent volatility in the stock has created an attractive entry point,” Mitchell wrote, while forecasting 2026 earnings of $5.68 per share versus a FactSet consensus of $5.29, according to the report. Barron’s

Friday’s jump left Vertiv back near levels that traders have treated as a pivot since late 2025, after a choppy stretch that had punished richly valued industrial technology names. The immediate question for Monday is whether buyers defend the $170 area — roughly Friday’s opening zone — if the broader market softens.

The next company catalyst is its 2026 outlook, which investors will pressure-test for order momentum, margins and the pace of liquid cooling adoption. Vertiv has not confirmed its next earnings publication date; market calendars estimate a report on Feb. 11.

Peers and adjacent “AI infrastructure” names have been moving on similar narratives — that spending shifts from chips to the power-and-cooling stack as data centers scale. Barclays framed Vertiv’s recent pullback as an opportunity to catch up with other industrial AI plays, Barron’s said.

Macro data could steer the tape this week as well. The U.S. Labor Department is scheduled to release the employment report for December 2025 on Friday, Jan. 9 at 8:30 a.m. ET, a print that can move Treasury yields and, in turn, rate-sensitive growth stocks.

The bigger rate marker later this month is the Federal Reserve’s Jan. 27-28 policy meeting. Any shift in the path for borrowing costs can change how investors value long-duration earnings stories like Vertiv’s.

Still, the bullish case hinges on data center customers sustaining capital spending and Vertiv translating demand into margins. A wobble in hyperscaler budgets, slower-than-expected liquid cooling adoption, or cautious guidance could unwind Friday’s momentum quickly.

When trading resumes, investors will watch whether Vertiv can build on the post-upgrade pop without fresh news — and whether the stock can reclaim round-number resistance near $180. The next scheduled catalysts are the Jan. 9 jobs report and the market’s expected mid-February earnings window.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
CrowdStrike stock fell 3% Friday — what to watch before markets reopen
Previous Story

CrowdStrike stock fell 3% Friday — what to watch before markets reopen

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop
Next Story

Cisco stock set for Monday spotlight after $2 billion Axonius deal report, ex-dividend drop

Go toTop